BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 10952495)

  • 21. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
    Brassard M; Borget I; Edet-Sanson A; Giraudet AL; Mundler O; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Toubert ME; Torlontano M; Benhamou E; Schlumberger M;
    J Clin Endocrinol Metab; 2011 May; 96(5):1352-9. PubMed ID: 21389143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma.
    Taylor T; Specker B; Robbins J; Sperling M; Ho M; Ain K; Bigos ST; Brierley J; Cooper D; Haugen B; Hay I; Hertzberg V; Klein I; Klein H; Ladenson P; Nishiyama R; Ross D; Sherman S; Maxon HR
    Ann Intern Med; 1998 Oct; 129(8):622-7. PubMed ID: 9786809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiated thyroid carcinoma in children and young adults: evaluation of response to treatment.
    Hod N; Hagag P; Baumer M; Sandbank J; Horne T
    Clin Nucl Med; 2005 Jun; 30(6):387-90. PubMed ID: 15891289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The clinical characteristics and treatment strategies of differentiated thyroid carcinoma in adolescents and children].
    Li SC; Li ZD; Liu HW; Dong HL; Xu Y
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Mar; 31(6):431-437. PubMed ID: 29871280
    [No Abstract]   [Full Text] [Related]  

  • 27. [Outcomes of long-term combined treatment in follicular thyroid carcinoma].
    Baranauskas Z; Valuckas KP; Tiskevicius S
    Medicina (Kaunas); 2010; 46(4):268-74. PubMed ID: 20571295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
    Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
    Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body Composition, Resting Energy Expenditure, and Metabolic Changes in Women Diagnosed with Differentiated Thyroid Carcinoma.
    Izkhakov E; Vaisman N; Barnes S; Barchana M; Stern N; Keinan-Boker L
    Thyroid; 2019 Aug; 29(8):1044-1051. PubMed ID: 31088334
    [No Abstract]   [Full Text] [Related]  

  • 30. Differentiated thyroid cancer in a Swedish county--long-term results and quality of life.
    Malterling RR; Andersson RE; Falkmer S; Falkmer U; Niléhn E; Järhult J
    Acta Oncol; 2010 May; 49(4):454-9. PubMed ID: 20092427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Draft of the best medical treatment in patients with low-risk thyroid cancer].
    Vlček P; Nováková D; Vejvalka J; Zimák J; Křenek M; Vošmiková K; Smutný S; Bavor P; Astl J; Lukáš J
    Vnitr Lek; 2015 Sep; 61(9):769-77. PubMed ID: 26465275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases.
    Mihailovic J; Stefanovic L; Malesevic M; Markoski B
    Thyroid; 2009 Mar; 19(3):227-32. PubMed ID: 19265493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma.
    Pelikan DM; Lion HL; Hermans J; Goslings BM
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):713-20. PubMed ID: 9497879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
    Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
    Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma.
    Sabet A; Binse I; Dogan S; Koch A; Rosenbaum-Krumme SJ; Biersack HJ; Biermann K; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):190-195. PubMed ID: 27530124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors affecting disease-free status of differentiated thyroid carcinoma patients.
    Thamnirat K; Utamakul C; Chamroonrat W; Kositwattanarerk A; Anongpornjossakul Y; Sritara C
    Asian Pac J Cancer Prev; 2015; 16(2):737-40. PubMed ID: 25684517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome.
    Haq M; Harmer C
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):87-93. PubMed ID: 15963067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved Survival After Multimodal Approach with
    Wu D; Gomes Lima CJ; Moreau SL; Kulkarni K; Zeymo A; Burman KD; Wartofsky L; Van Nostrand D
    Thyroid; 2019 Jul; 29(7):971-978. PubMed ID: 31017051
    [No Abstract]   [Full Text] [Related]  

  • 39. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
    Yap BK; Murby B
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.
    Lang BH; Lo CY; Chan WF; Lam KY; Wan KY
    Ann Surg Oncol; 2007 Feb; 14(2):730-8. PubMed ID: 17103065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.